Contact PD/PI: Murphy, Timothy F The Buffalo Translational Consortium (BTC), which includes the University at Buffalo (UB) health sciences schools, the major healthcare institutions in our region, four key research institutes and five influential community partners, have embarked on a comprehensive strategic plan to build a strong foundation for clinical and translational research in response to our community needs. Buffalo is the second most populous city in New York State and has a rich cultural history. The proportion of underrepresented minorities in Buffalo in 2018 (50%) parallels that projected for the US in 2050, making Buffalo a microcosm of what the US will look like in 30 years. A similar proportion of our population experiences health disparities. The vision for our CTSA hub is to perform innovative research across the translational spectrum to improve the health of our community and the nation. We will develop, test and share novel approaches to engage difficult-to-engage populations and reduce health disparities in our community, which represents a ?population of the future?. Guided by our vision, the CTSA has catalyzed a transformation of our environment since our CTSA was first funded in August 2015 with remarkable growth in clinical and translational research. Further, in just the past year, the UB medical school has moved into a spectacular new building and our clinical partner, Kaleida Health, the largest healthcare system in the region, opened the new Oishei Children?s Hospital, both on the Buffalo Niagara Medical Campus and connected to the Clinical and Translational Research Center devoted entirely to clinical and translational research that opened in 2012. This rapid and continuing trajectory of growth in healthcare and research in the region has resulted in a new 21st century Academic Health Center with healthcare, medical education and clinical and translational research on one campus in the heart of Buffalo, creating a foundation to enhance the impact of our CTSA even further. While launching our CTSA, we have prioritized participation in the national consortium through hosting and testing Innovation Labs as a team science tool, working with multiple hubs on initiatives to solve translational research barriers and sharing tools that we have developed with the CTSA consortium, including novel health informatics tools. Our CTSA has five ambitious but achievable aims, including: 1) Accelerate innovative translational research with teams that engage communities, regional stakeholders and the national consortium; 2) Train an excellent, diverse workforce to advance translation of discoveries; 3) Enhance inclusion of special populations across the lifespan and difficult-to-engage populations; 4) Streamline clinical research processes focusing on quality and efficiency with emphasis on multisite studies; 5) Develop, test and share biomedical informatics tools to integrate data from multiple sources to speed translation. Guided by our vision to perform research to improve the health of our community and the nation, we will continue our momentum to expand translational research, train our diverse workforce, streamline processes, engage our community, and actively contribute to the national consortium. Page 243 Project Summary/Abstract Contact PD/PI: Murphy, Timothy F The University at Buffalo Clinical and Translational Science Institute (CTSI) is the coordinating center of the Buffalo Translational Consortium, which includes the region's premier research, educational and clinical institutions with influential community partners. The vision of the CTSI is to perform innovative clinical and translational research to reduce health disparities and improve the health of our community and the nation. We engage our community as research partners to create a shared environment to bring discoveries in the laboratory, clinic and community to benefit individual and public health. Page 244

Public Health Relevance

The University at Buffalo Clinical and Translational Science Institute (CTSI) is the coordinating center of the Buffalo Translational Consortium, which includes the region's premier research, educational and clinical institutions with influential community partners. The vision of the CTSI is to perform innovative clinical and translational research to reduce health disparities and improve the health of our community and the nation. We engage our community as research partners to create a shared environment to bring discoveries in the laboratory, clinic and community to benefit individual and public health.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
5UL1TR001412-06
Application #
10103865
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Doyle, Jamie Mihoko
Project Start
2015-08-12
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
6
Fiscal Year
2021
Total Cost
Indirect Cost
Name
State University of New York at Buffalo
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
038633251
City
Amherst
State
NY
Country
United States
Zip Code
14228
Jacobs, David M; Noyes, Katia; Zhao, Jiwei et al. (2018) Early Hospital Readmissions after an Acute Exacerbation of Chronic Obstructive Pulmonary Disease in the Nationwide Readmissions Database. Ann Am Thorac Soc 15:837-845
Welliver, R Ross; Polanco, Jessie J; Seidman, Richard A et al. (2018) Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci :
Jacobs, David M; Ochs-Balcom, Heather M; Zhao, Jiwei et al. (2018) Lower Airway Bacterial Colonization Patterns and Species-Specific Interactions in Chronic Obstructive Pulmonary Disease. J Clin Microbiol 56:
Gallo, Mary C; Kirkham, Charmaine; Eng, Samantha et al. (2018) Changes in IgA Protease Expression Are Conferred by Changes in Genomes during Persistent Infection by Nontypeable Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Infect Immun 86:
Langkammer, Christian; Schweser, Ferdinand; Shmueli, Karin et al. (2018) Quantitative susceptibility mapping: Report from the 2016 reconstruction challenge. Magn Reson Med 79:1661-1673
Bailey, Daniel C; Buckley, Brian P; Chernov, Mikhail V et al. (2018) Development of a High-Throughput Biochemical Assay to Screen for Inhibitors of Aerobactin Synthetase IucA. SLAS Discov 23:1070-1082
Guo, Xiaojuan; Chen, Xushen; Wang, Jie et al. (2018) Multi-generational impacts of arsenic exposure on genome-wide DNA methylation and the implications for arsenic-induced skin lesions. Environ Int 119:250-263
Curtis, Anne B; Karki, Roshan; Hattoum, Alexander et al. (2018) Arrhythmias in Patients ?80 Years of Age: Pathophysiology, Management, and Outcomes. J Am Coll Cardiol 71:2041-2057
Weil, Brian R; Suzuki, Gen; Young, Rebeccah F et al. (2018) Troponin Release and Reversible Left Ventricular Dysfunction After Transient Pressure Overload. J Am Coll Cardiol 71:2906-2916
Bailey, Daniel C; Alexander, Evan; Rice, Matthew R et al. (2018) Structural and functional delineation of aerobactin biosynthesis in hypervirulent Klebsiella pneumoniae. J Biol Chem 293:7841-7852

Showing the most recent 10 out of 238 publications